Trial Profile
Phase IIa, multicenter, randomised, double-blind, placebo controlled study of the efficacy and safety of RO0506997, an α4 integrin antagonist, in combination with methotrexate, versus methotrexate alone, in patients with mild/moderate active rheumatoid arthritis (RA) who have had a partial response to a stable dose of methotrexate.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2011
Price :
$35
*
At a glance
- Drugs RO 0506997 (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Roche
- 21 Jun 2011 New trial record